GEN Exclusives

More »

The Lists

More »
Dec 9, 2013

Top 30 Venture Capital Firms of 2013

Who are the big spenders that help grease the wheels of biotech?

Top 30 Venture Capital Firms of 2013

This year’s list has been expanded to a top 30 in part to include the higher number of firms with funds totaling more than $1.1 billion compared with 2012. [Bobby4237 - Fotolia.com]

  • #20. SV Life Sciences

    City (cities) where offices are located: Boston; San Francisco, CA; London

    Fund size and status: Approximately $2 billion under management across five funds

    Current fund: $524 million SV Life Sciences Fund V, closed 2010; fund includes $513 million, plus $11 million of co-investments committed by partners and individuals affiliated with SVLS

    Current biopharma portfolio companies: Achillion Pharmaceuticals, Aderis Pharmaceuticals, Adimab, Affibody, Affinium Pharmaceuticals, Alantos Pharmaceuticals, Alba Therapeutics, Alinea Pharmaceuticals, Allocure, Allos Therapeutics, Antiva, Archemix, Arsanis Biosciences, Atopix Therapeutics/Oxagen, Autifony Therapeutics, Auxilium, Avera Pharmaceuticals, Avitide, Axys, Bicycle Therapeutics, BioClinica, Calchan Holdings, Catabasis Pharmaceuticals, Celerion, Cellzome, Convergence Pharmaceuticals, Coral Therapeutics, Cyterix Pharmaceuticals, Delenex Therapeutics, Dynogen Pharmaceuticals, EUSA Pharma, Good Start Genetics, Ikano Therapeutics, Imagen Biotech, Itero Biopharmaceuticals, Juvaris Biotherapeutics, KalVista Pharmaceuticals, Karus Therapeutics, Link Medicine, Logical Therapeutics, Lux Biosciences, Metris Therapeutics, Micromet, Mpex Pharmaceuticals, NeurogesX, Neurotech, NKT Therapeutics, Oncoethix, Ophthotech, PanOptica, Rempex Pharmaceuticals, Shire Pharmaceuticals, Sutro Biopharma, TopiVert, Trine Pharmaceuticals, Vantia Pharmaceuticals, Vernalis, X2-Pharma

    Typical investment range: Firm primarily invests between $1 million and $40 million in North American and European companies, but will consider “innovative” investments in other regions

    Year established: Established 1993 as Schroder Ventures Life Sciences, part of the Schroder Ventures Group. SVLS became independent of the Schroder Ventures Group in 2001, and changed its name in 2005

  • #19. Alta Partners

    City (cities) where offices are located: San Francisco

    Fund size and status: $2 billion under management across eight funds

    Current fund: $500 million Alta Partners VIII, a first stage-independent life sciences fund closed 2006

    Current biopharma portfolio companies: 7TM Pharma, Ablynx, AcelRx Pharmaceuticals, Achaogen, Aegerion Pharmaceuticals, Aerie Pharmaceuticals, Aerovance, Alba Therapeutics, Allakos, Applied Genetic Technologies (AGTC), Astex Pharmaceuticals, aTyr Pharma, Azelon Pharmaceuticals, Cara Therapeutics, Ceregene, Cerenis Therapeutics, ChemoCentryx, Chimerix, Corcept Therapeutics, CymaBay Therapeutics (formerly Metabolex), Cytokinetics, DiscoveRx, Esperion Therapeutics, Excaliard Pharmaceuticals, Genedata, Immune Design, Intarcia Therapeutics, Kiadis Pharma, Kite Pharma, Lithera, Lumena Pharmaceuticals, MacroGenics, Nereus Pharmaceuticals, Pathwork Diagnostics, Portola Pharmaceuticals, Proacta Therapeutics, Prolacta Bioscience, Scynexis, Silence Therapeutics, Sonexa Therapeutics, Sunesis Pharmaceuticals, Sutro Biopharma, Threshold Pharmaceuticals, Trevena, Veloxis, ViroBay, VitrOmics

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1996

  • #18. Third Security

    City (cities) where offices are located: Radford, VA; San Francisco; Palm Beach, FL

    Fund size and status: More than $2 billion under management through nine affiliated investment funds, consisting of seven New River Management Funds and two regional funds

    Current New River Management Funds: $120 million New River Management VII, closed 2012; $15 million Valleys’ Ventures, launched May 2013 to invest in companies that intend to commence operations in, or are willing to relocate to an area within 100 miles of Montgomery, Roanoke or Botetourt counties of southwestern Virginia

    Current biopharma portfolio companies: AmpliPhi Biosciences, Biolife Cell Bank, Fibrocell Science, Halozyme Therapeutics, Intrexon, Oragenics, Soligenix, Synthetic Biologics

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1999

  • #17. Mohr Davidow Ventures

    City (cities) where offices are located: Menlo Park, CA

    Fund size and status: More than $2 billion under management in nine funds

    Most recent fund: $670 million MDV IX fund, first closed 2007 at $580 million. In January 2013, the firm reduced its MDV VII fund to $450 million from $670 million; Fund VII was reduced once before, in 2012, from its initial $840 million close

    Current biopharma portfolio companies: Adamas, CardioDx, Crescendo Bioscience, Pacific Biosciences, Personalis, RainDance Technologies, Tethys Bioscience

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1983

  • #16. Frazier Healthcare

    City (cities) where offices are located: Seattle and Menlo Park, CA

    Fund size and status: More than $2 billion under management across seven funds

    Current fund: $377 million Frazier Healthcare VII, closed September 2013

    Current biopharma portfolio companies: Achaogen, Alcresta, Allena Pharmaceuticals, Amicus Therapeutics, Anaptys, Attercor, Cadence Pharmaceuticals, Chimerix, Collegium Pharmaceutical, Portola Pharmaceuticals, QuatRx, Rempex Pharmaceuticals, Semnur Pharmaceuticals, Silvergate Pharmaceuticals, Tobira Therapeutics, VentiRx Pharmaceuticals

    Typical investment range: Growth equity investment commitments have ranged between $20 million and $50 million; venture investment average or range per-company unavailable. Since 2002, firm has been founding investor in more than 50% of its biopharma portfolio companies, and lead investor in more than 75% of these companies.

    Year established: 1991

  • #15. Venrock

    City (cities) where offices are located: Cambridge, MA; New York; Palo Alto, CA

    Fund size and status: $2.2 billion under management across six funds

    Current fund: $350 million Venrock VI, closed 2010

    Current biopharma portfolio companies: Acceleron Pharma, Achaogen, Anacor Pharmaceuticals, Ariosa Diagnostics, AVEO Pharma, Celladon, Cerulean, Constellation Pharmaceuticals, CymaBay Therapeutics (formerly Metabolex), Fate Therapeutics, Hua Medicine, Ikaria, Infinity Pharmaceuticals, Intarcia Therapeutics, Ironwood Pharma, Pathwork Diagnostics, QuatRx, Receptos, Vitae Pharmaceuticals

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1969

  • #14. Morgenthaler Ventures — Life Sciences Team

    City (cities) where offices are located: Palo Alto, CA; Boston; Boulder, CO

    Fund size and status: $2.5 billion under management

    Current fund: $400 million Fund IX, closed 2008 and used in part for investment in life-sciences companies. The general partners of the Life Sciences team and Advanced Technology Ventures joined investors from both in 2012 to create a new firm, Lightstone Ventures, which has declined comment on a news report that it is close to raising $150 million.3

    Current biopharma portfolio companies: Calithera Biosciences, Catalyst Biosciences, Elcelyx Therapeutics, Galleon Pharmaceuticals, GlobeImmune, Mosaic Biosciences, OncoMed Pharmaceuticals, Orexigen, Principia Biopharma, Promedior Pharmaceuticals, Ra Pharmaceuticals, Replidyne, Ribozyme Pharmaceuticals, Scioderm, Stemgent, Threshold Pharmaceutical, Tragara Pharmaceuticals, Trellis Bioscience, Vical

    Typical investment range: Between $12 million and $15 million total investment per company over several rounds; predominantly Series A, but open to later-stage investments: “In biotech, we look for multi-product platforms, or targeted therapies, that can achieve clinical proof of principle within five years.”

    Year established: 1968

  • #13. Essex Woodlands Health Ventures

    City (cities) where offices are located: Palo Alto, CA; New York; Houston; London; Shanghai

    Fund size and status: More than $2.5 billion under management across eight funds

    Current fund: $900 million Fund VIII, closed 2009; firm declined comment in October on a published report that it was seeking capital from investors for $750 million ninth fund4

    Current biopharma portfolio companies: Acura Pharmaceuticals (formerly Halsey Drug), Biotoscana, Catalyst Biosciences, Chroma Therapeutics, Corium (formerly Stratagent Life Sciences), Curis (formerly Reprogenesis), Elusis Therapeutics (formerly E-Site Therapeutics), EUSA Pharma, Horizon Pharma (formerly Horizon Therapeutics), IntegenX, LightSciences Oncology, Medicinova, Molecular Partners, Open Monoclonal Technology, Palatin, Palmetto Pharmaceuticals (formerly eNOS Pharmaceuticals), Parexel, PreCision Dermatology, ProteinSimple, Revance Therapeutics (formerly Essentia BioSystems), Serene Oncology, Symphogen, Xanodyne Pharmaceuticals (formerly Integrity Pharmaceuticals), Repros Therapeutics (formerly Zonagen), Ziopharm Oncology

    Typical investment range: Venture investment average or range per-company unavailable; growth equity investments typically range from $20 million to $60 million, with the firm capable of investing up to $100 million per deal

    Year established: 1985

  • #12. MPM Capital

    City (cities) where offices are located: Boston; South San Francisco, CA; Munich; Gainesville, FL; Kansas City, KS

    Fund size and status: More than $2.6 billion committed capital under management across five funds

    Current fund: Approximately $300 million MPM BioVentures V L.P., closed 2010

    Current biopharma portfolio companies: Aires Pharmaceuticals, Allozyne, Amphivena Therapeutics, Anthera Pharmaceuticals, Aveo Oncology, Celladon, Ceregene, Chiasma, Colucid Pharmaceuticals, Conatus Pharmaceuticals, Costin Pharmaceuticals, EKR Therapeutics, Epigenomics, Epizyme, Idenix Pharmaceuticals, iPierian, Kalidex Pharmaceuticals, KaloBios Pharmaceuticals, Macrogenics, Mitokyne, NeuroTherapeutics Pharma, Oxagen, Pacira Pharmaceuticals, Pharmathene, Poniard Pharmaceuticals, Portola Pharmaceuticals, Proteon Therapeutics, QuatRx Pharmaceuticals, Radius Health, Rhythm Pharmaceuticals, Selexys Pharmaceuticals, Sideris Pharmaceuticals, Solasia Pharma, Swedish Orphan BioVitrum, Syndax Pharmaceuticals, Theraclone Sciences, Verastem, VLST, Xanodyne Pharmaceuticals, Zalicus (formerly CombinatoRx)

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1996

  • #11. Domain Associates

    City (cities) where offices are located: Princeton, NJ, and San Diego

    Fund size and status: More than $2.7 billion under management across eight funds

    Current fund: $500 million Domain Partners VIII, closed 2009

    Current biopharma portfolio companies: Achaogen, Achillion Pharmaceuticals, Adynxx, Afferent Pharmaceuticals, Aldexa Therapeutics, Alimera Sciences, Applied Proteomics, Ariosa Diagnostics, Ascenta Therapeutics, Asmacure, Astute Medical, Atara Biotherapeutics, aTyr Pharma, BioNano Genomics, Cadence Pharmaceuticals, Cantex Pharmaceuticals, Celator Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, CoLucid Pharmaceuticals, Corridor Pharmaceuticals, Dicerna Pharmaceuticals, Domain Elite Holdings, Domain Russia Investments, Durata Therapeutics, Eddingpharm International Holdings, Epic Sciences, Esperion Therapeutics, Evoke Pharma, Five Prime Therapeutics, IntegenX, Lithera, Marinus Pharmaceuticals, Meritage Pharma, NovaDigm Therapeutics, Ocera Therapeutics, Oraya Therapeutics, Orexigen Therapeutics, Otonomy, ProteinSimple, Regardo Biosciences, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals, VentiRx Pharmaceuticals, Veracyte, Zogenix

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1985



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?